PE20160877A1 - Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion - Google Patents
Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacionInfo
- Publication number
- PE20160877A1 PE20160877A1 PE2016000398A PE2016000398A PE20160877A1 PE 20160877 A1 PE20160877 A1 PE 20160877A1 PE 2016000398 A PE2016000398 A PE 2016000398A PE 2016000398 A PE2016000398 A PE 2016000398A PE 20160877 A1 PE20160877 A1 PE 20160877A1
- Authority
- PE
- Peru
- Prior art keywords
- amino acids
- sequence
- heterogenic
- populations
- recombinant human
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Water Supply & Treatment (AREA)
- Toxicology (AREA)
Abstract
SE REFIERE A COMPOSICIONES QUE COMPRENDEN VARIANTES RECOMBINANTES DEL FACTOR XA COAGULANTE HUMANO TALES COMO A) LA FORMA BETA DE LA PROTEINA VARIANTE DE FXA EN DONDE LA SECUENCIA DE PROTEINA DE CADENA LIGERA Y CADENA PESADA RESPECTIVAMENTE CONSISTEN DE AMINOACIDOS 1 A 139 Y 146 A 386, AMINOACIDOS 1 A 140 Y 146 A 384, AMINOACIDOS 1 A 140 Y 146 A 386, AMINOACIDOS 1 A 141 Y 146 A 384, AMINOACIDOS 1 A 141 Y 146 A 386, ENTRE OTROS, DE LA SECUENCIA DE AMINOACIDO SEC ID N°: 1; Y B) LA FORMA ALFA DE LA PROTEINA VARIANTE DE FXA EN DONDE LA SECUENCIA DE PROTEINA DE CADENA LIGERA Y CADENA PESADA RESPECTIVAMENTE CONSISTEN DE AMINOACIDOS 1 A 139 Y 146 A 398, AMINOACIDOS 1 A 140 Y 146 A 398, AMINOACIDOS 1 A 140 Y 146 A 399, AMINOACIDOS 1 A 141 Y 146 A 398, ENTRE OTROS, DE LA SECUENCIA DE AMINOACIDO SEC ID N°: 1. DICHAS COMPOSICIONES SON UTILES PARA EL TRATAMIENTO DE HEMOFILIA A Y B
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361881834P | 2013-09-24 | 2013-09-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20160877A1 true PE20160877A1 (es) | 2016-09-11 |
Family
ID=51844797
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2016000398A PE20160877A1 (es) | 2013-09-24 | 2014-09-16 | Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9757434B2 (es) |
| EP (1) | EP3049434A1 (es) |
| JP (1) | JP6429885B2 (es) |
| KR (1) | KR101988705B1 (es) |
| CN (2) | CN105579468A (es) |
| AR (1) | AR097732A1 (es) |
| AU (1) | AU2014326257B2 (es) |
| BR (1) | BR112016005899A8 (es) |
| CA (1) | CA2924981C (es) |
| HK (1) | HK1218760A1 (es) |
| IL (2) | IL244258A0 (es) |
| MX (1) | MX373466B (es) |
| MY (1) | MY173548A (es) |
| PE (1) | PE20160877A1 (es) |
| RU (1) | RU2648144C2 (es) |
| SA (1) | SA516370751B1 (es) |
| SG (1) | SG11201601221XA (es) |
| TW (1) | TWI631134B (es) |
| WO (1) | WO2015044836A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2015008813A (es) | 2013-01-31 | 2016-03-31 | Pfizer | Composiciones y metodos para contrarrestar la inhibicion del factor xa. |
| RU2648144C2 (ru) | 2013-09-24 | 2018-03-22 | Пфайзер Инк. | КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ГЕТЕРОГЕННЫЕ ПОПУЛЯЦИИ РЕКОМБИНАНТНЫХ БЕЛКОВ ЧЕЛОВЕЧЕСКОГО ФАКТОРА СВЕРТЫВАНИЯ КРОВИ Ха |
| US10604748B2 (en) | 2016-06-17 | 2020-03-31 | Portola Pharmaceuticals, Inc. | Preparation of factor Xa derivatives |
| EP3722418A1 (en) * | 2019-04-08 | 2020-10-14 | AB Enzymes Oy | Solution stable enzyme composition |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5597799A (en) | 1990-09-04 | 1997-01-28 | Cor Therapeutics, Inc. | Recombinant agents affecting thrombosis |
| AT405517B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-deletionsmutanten und analoge davon |
| AT405516B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-analoge mit modifizierter proteasespaltstelle |
| AT410216B (de) | 1999-08-10 | 2003-03-25 | Baxter Ag | Faktor x-analogon mit verbesserter aktivierbarkeit |
| US20040102388A1 (en) | 2000-03-22 | 2004-05-27 | High Katherine A. | Modified blood clotting factors and methods of use |
| FR2831170B1 (fr) | 2001-10-19 | 2004-03-19 | Inst Nat Sante Rech Med | Proteines c modifiees activables directement par la thrombine |
| FR2841904B1 (fr) | 2002-07-03 | 2004-08-20 | Inst Nat Sante Rech Med | Analogues de facteurs x clivables par la thrombine |
| BRPI0514396A2 (pt) * | 2004-08-17 | 2009-05-12 | Csl Behring Gmbh | polipeptìdeos dependentes de vitamina k modificada |
| EP1728798A1 (en) | 2005-06-01 | 2006-12-06 | ZLB Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| MX2008006313A (es) | 2005-11-15 | 2008-11-06 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
| EP1820508A1 (en) | 2006-02-21 | 2007-08-22 | CSL Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| JP5637561B2 (ja) * | 2007-09-28 | 2014-12-10 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 第Ｘａ因子阻害剤に対する解毒剤およびその使用の方法 |
| PT2300497E (pt) | 2008-06-24 | 2012-10-30 | Octapharma Ag | Processo de purificação do factor viii de coagulação |
| US8455439B2 (en) | 2008-11-14 | 2013-06-04 | Portola Pharmaceuticals, Inc. | Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents |
| CN102325880B (zh) | 2008-12-19 | 2014-10-01 | 国家健康与医学研究院 | 丝氨酸蛋白酶衍生物及其在凝血功能障碍的预防或治疗中的用途 |
| JP6163304B2 (ja) * | 2009-07-15 | 2017-07-12 | ポートラ ファーマシューティカルズ， インコーポレイテッド | 第Ｘａ因子インヒビターの解毒剤の単位用量処方物およびその使用方法 |
| PT2591006T (pt) * | 2010-07-09 | 2019-07-29 | Bioverativ Therapeutics Inc | Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas |
| FR2972114B1 (fr) | 2011-03-01 | 2013-03-15 | Univ Grenoble 1 | Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur |
| EP2760887B1 (en) * | 2011-09-30 | 2024-10-23 | The Children's Hospital of Philadelphia | Compositions and methods for modulating hemostasis |
| ES2704083T3 (es) | 2012-07-25 | 2019-03-14 | Catalyst Biosciences Inc | Polipéptidos de factor x modificados y usos de los mismos |
| MX2015008813A (es) | 2013-01-31 | 2016-03-31 | Pfizer | Composiciones y metodos para contrarrestar la inhibicion del factor xa. |
| RU2648144C2 (ru) | 2013-09-24 | 2018-03-22 | Пфайзер Инк. | КОМПОЗИЦИИ, СОДЕРЖАЩИЕ ГЕТЕРОГЕННЫЕ ПОПУЛЯЦИИ РЕКОМБИНАНТНЫХ БЕЛКОВ ЧЕЛОВЕЧЕСКОГО ФАКТОРА СВЕРТЫВАНИЯ КРОВИ Ха |
| US20160235824A1 (en) | 2013-11-01 | 2016-08-18 | The Children's Hospital Philadelphia | Compositions and Methods for Increasing the Half-Life of Factor XA |
| BR112016014617A2 (pt) | 2014-01-24 | 2017-09-19 | Pfizer | Variante do fator xa (fxa) e usos da referida variante |
-
2014
- 2014-09-16 RU RU2016108608A patent/RU2648144C2/ru active
- 2014-09-16 WO PCT/IB2014/064564 patent/WO2015044836A1/en not_active Ceased
- 2014-09-16 KR KR1020167007373A patent/KR101988705B1/ko not_active Expired - Fee Related
- 2014-09-16 CN CN201480052212.2A patent/CN105579468A/zh active Pending
- 2014-09-16 CN CN202011112690.1A patent/CN112195169A/zh active Pending
- 2014-09-16 CA CA2924981A patent/CA2924981C/en not_active Expired - Fee Related
- 2014-09-16 PE PE2016000398A patent/PE20160877A1/es unknown
- 2014-09-16 EP EP14792595.2A patent/EP3049434A1/en not_active Withdrawn
- 2014-09-16 SG SG11201601221XA patent/SG11201601221XA/en unknown
- 2014-09-16 BR BR112016005899A patent/BR112016005899A8/pt not_active IP Right Cessation
- 2014-09-16 JP JP2016543477A patent/JP6429885B2/ja not_active Expired - Fee Related
- 2014-09-16 AU AU2014326257A patent/AU2014326257B2/en not_active Ceased
- 2014-09-16 MY MYPI2016700985A patent/MY173548A/en unknown
- 2014-09-16 HK HK16106674.2A patent/HK1218760A1/zh unknown
- 2014-09-16 MX MX2016003871A patent/MX373466B/es active IP Right Grant
- 2014-09-23 TW TW103132803A patent/TWI631134B/zh not_active IP Right Cessation
- 2014-09-23 AR ARP140103512A patent/AR097732A1/es unknown
- 2014-09-24 US US14/495,478 patent/US9757434B2/en not_active Expired - Fee Related
-
2016
- 2016-02-23 IL IL244258A patent/IL244258A0/en unknown
- 2016-03-17 SA SA516370751A patent/SA516370751B1/ar unknown
-
2017
- 2017-08-04 US US15/669,340 patent/US10660946B2/en active Active
-
2020
- 2020-05-25 US US16/882,598 patent/US20210106658A1/en not_active Abandoned
- 2020-12-13 IL IL279396A patent/IL279396A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2016535071A (ja) | 2016-11-10 |
| IL279396A (en) | 2021-01-31 |
| MX2016003871A (es) | 2016-08-04 |
| US10660946B2 (en) | 2020-05-26 |
| TW201524996A (zh) | 2015-07-01 |
| US20210106658A1 (en) | 2021-04-15 |
| CA2924981A1 (en) | 2015-04-02 |
| CA2924981C (en) | 2020-03-31 |
| US20170333535A1 (en) | 2017-11-23 |
| AU2014326257B2 (en) | 2017-08-10 |
| MY173548A (en) | 2020-02-04 |
| KR101988705B1 (ko) | 2019-06-12 |
| RU2648144C2 (ru) | 2018-03-22 |
| SG11201601221XA (en) | 2016-04-28 |
| JP6429885B2 (ja) | 2018-11-28 |
| RU2016108608A (ru) | 2017-10-26 |
| KR20160044034A (ko) | 2016-04-22 |
| CN105579468A (zh) | 2016-05-11 |
| BR112016005899A8 (pt) | 2018-02-06 |
| TWI631134B (zh) | 2018-08-01 |
| IL244258A0 (en) | 2016-04-21 |
| AR097732A1 (es) | 2016-04-13 |
| MX373466B (es) | 2020-05-25 |
| US9757434B2 (en) | 2017-09-12 |
| BR112016005899A2 (pt) | 2017-09-26 |
| US20150182604A1 (en) | 2015-07-02 |
| CN112195169A (zh) | 2021-01-08 |
| HK1218760A1 (zh) | 2017-03-10 |
| SA516370751B1 (ar) | 2018-04-05 |
| EP3049434A1 (en) | 2016-08-03 |
| AU2014326257A1 (en) | 2016-03-10 |
| WO2015044836A1 (en) | 2015-04-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UY39119A (es) | Proteínas de fusión para tratar trastornos metabólicos | |
| CL2011003003A1 (es) | Composicion tensioactiva reconstituida que comprende un polipeptido análogo a la proteína surfactante c nativa, un polipeptido análogo a la proteína surfactante b nativa, un fosfolipido monoinsaturado y un fosfolipido saturado, útil para el tratamiento del síndrome de dificultad respiratoria. | |
| PE20140982A1 (es) | Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta | |
| CO7051009A2 (es) | Composiciones del factor viii y métodos para hacerlas y usarlas | |
| SV2018005714A (es) | Composiciones y metodos para disminuir la expresion de tau | |
| CR20130234A (es) | Métodos de tratamiento de trastornos asociados con el fgf21 | |
| MX366906B (es) | Purificacion de iduronato-2-sulfatasa. | |
| MX2018012166A (es) | Dosificacion oral de compuestos peptido similar al glaucon-1 (glp-1). | |
| EA201290964A1 (ru) | Пептидные конъюгаты агонистов рецептора glp-1 и их применение | |
| EA201491856A1 (ru) | Терапевтическое применение белков фактора роста фибробластов 21 | |
| TR201815173T4 (tr) | Peptit bileşimleri. | |
| MX2020000083A (es) | Factor de von willebrand recombinante ( rvwf ) y factor viii recombinante ( rfviii ) para usarse en un metodo para tratar la enfermedad de von willebrand. | |
| EA201890815A1 (ru) | Аминокислотные композиции с модифицированным высвобождением для перорального введения | |
| GT201700224A (es) | Proteína de unión a rgma y su uso | |
| PE20200894A1 (es) | Polipeptidos variantes del factor de crecimiento tipo insulina 1 | |
| MX2019001633A (es) | Proteina derivada de la seda para el tratamiento de la inflamacion. | |
| BR112017014580A8 (pt) | Método para obter um isolado peptídico a partir de uma biomassa de microalgas enriquecidas com proteína | |
| PE20130379A1 (es) | Metodos para el tratamiento de las ulceras del pie diabetico | |
| PE20160877A1 (es) | Composiciones que comprenden poblaciones heterogeneas de proteinas recombinantes humanas de factor xa de coagulacion | |
| AR094835A1 (es) | Péptidos bioactivos cortos que promueven la cicatrización de las heridas | |
| EA201690191A1 (ru) | Фармацевтическая композиция для замедленного высвобождения ланреотида | |
| EA201590601A1 (ru) | Применение pedf-производных полипептидов для лечения остеоартрита | |
| AR092736A1 (es) | Combinaciones farmaceuticas que comprenden aglutinantes duales de angiopoyetina-2 / dll4 y agentes anti-vegf-r | |
| PL3648788T3 (pl) | Leczenie krwawienia z przewodu pokarmowego u pacjentów z ciężką chorobą von willebranda poprzez podanie rekombinowanego vwf | |
| PE20160847A1 (es) | Nuevo compuesto para el tratamiento de hipoglicemia severa |